**Proteins** 

## **Product** Data Sheet



## LY117018

Cat. No.: HY-116896 CAS No.: 63676-25-5 C<sub>27</sub>H<sub>25</sub>NO<sub>4</sub>S Molecular Formula:

Molecular Weight: 459.56

Target: Estrogen Receptor/ERR

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of

## **BIOLOGICAL ACTIVITY**

Description	LY117018, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 exerts antiproliferative effects on breast cancer cell lines $^{[1][2]}$ .	
IC <sub>50</sub> & Target	Estrogen receptor	
In Vitro	LY117018 (0.01-1000 nM; 24 hours) at lower concentrations (0.01-10 nM) caused an E2-like increase in p53 levels when compared to its effects on cells grown in the stripped medium. At a higher concentration of LY117018 (1 $\mu$ M), the level of p53 appeared to decline. Treatment with 1 $\mu$ M LY117018 resulted in a predominantly hypophosphorylated pRb. At lower concentrations, LY117018 did not block E2-induced pRb phosphorylation <sup>[1]</sup> . LY117018 (1 $\mu$ M; 96 hours) inhibits MCF-7 cells proliferation with an IC <sub>50</sub> of 1 $\mu$ M <sup>[2]</sup> . LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay <sup>[2]</sup>	
	Cell Line:	MCF-7 cells
	Concentration:	1 μΜ
	Incubation Time:	96 hours
	Result:	Inhibited MCF-7 cells proliferation with an IC $_{50}$ of 1 $\mu\text{M}.$

## **REFERENCES**

[1]. Dinda S, et al. Effects of LY117018 (a SERM analog of raloxifene) on tumor suppressor proteins and proliferation of breast cancer cells. Horm Mol Biol Clin Investig. 2010 Aug 1;2(1):211-7.

[2]. Baumann KH, et al. Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Breast Cancer (Auckl). 2009 Apr 7;3:23-34.

[3]. Yu J, et al.Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway.Eur J Pharmacol. 2008 Jul 28:589(1-3):32-6.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com